Ashley Chan

King Charles III received a diagnosis of cancer after a procedure for an enlarged prostate, although Buckingham Palace specified that the king does not have prostate cancer.

Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said.

Patients with neuroendocrine tumors or neuroblastoma could be treated with a different approach based on a protein that may be a potential biomarker.

Some treatment-related cardiovascular events, such as atrial fibrillation, may be more common in patients with non-small cell lung cancer, research shows.

The treatment combination of avutometinib and Lumakras has been granted a Fast Track designation from the FDA in some with metastatic NSCLC.

Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.

It’s important to know what kinds of treatments are available for bladder cancer and understand that having a “tailored” treatment is important for patients, experts said.

In patients with TRK fusion GI cancers, Vitrakvi continued to show improvements regarding responses to treatment, survival and safety, research found.

Some with metastatic cancers receiving end-of-life-initiated immunotherapy may have a decreased risk of mortality when treated at a high-volume facility, research found.

Cancer survivors may face different mental and physical quality of life depending on their socioeconomic factors and age, according to a recent study.

Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

Recent research determined that two specific biomarkers may help predict and protect survivors of childhood cancer from heart risks, such as cardiomyopathy.

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer.

Newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia had better outcomes when receiving Scemblix, compared with a different TKI, a study found.

Recent research showed that Keytruda plus chemotherapy was superior to placebo plus chemotherapy in GI cancers, although the results were not considered statistically significant.

A phase 1/2 trial evaluating seclidemstat plus Vidaza resumed patient enrollment for those with certain blood cancers and another phase 1/2 trial demonstrated improved results in patients with Ewing sarcomas.

An expert explained why chemotherapy-related amenorrhea in premenopausal women with breast cancer is “not just about having a period.”

A patient in a phase 2 trial has received the first dose of a novel cancer vaccine plus Keytruda for solid skin cancer tumors.

The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).

The RELATIVITY-123 trial evaluating Opdualag in metastatic microsatellite stable colorectal cancer ended prematurely, according to the drug’s manufacturer.

Menin inhibitors for patients with AML have been one of many improvements within the blood cancer space this year, Lee Greenberger of the Leukemia and Lymphoma Society told CURE®.

The Gilotrif-Erbitux treatment combination demonstrated antitumor activity in patients with EGFR exon 20 insertion-positive NSCLC, according to a recent study.

Retevmo as a treatment for patients with advanced RET-mutant medullary thyroid cancer “is very exciting,” as treatment options were previously limited, an expert told CURE®.

Last Christmas, Cathy McQueen didn’t “feel so great” and noticed a strange indent on her right breast — quickly finding out she had a form of breast cancer.

A phase 2a trial administered the novel drug HT-6184 to its first patient with lower-risk myelodysplastic syndromes.

Treatment with Welireg — now approved by the FDA — helped shrink and stabilize tumors from metastatic renal cell carcinoma with minimal side effects, a patient told CURE®.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.